Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Opthotech Boosts IPO Size to as Much as $152 Million

Sept. 24 (Bloomberg) -- Opthotech Corp., developer of eye-disease treatments, boosted the amount it plans to raise from a U.S. initial public offering to as much as $152 million.

The company is offering 7.6 million shares for $19 to $20 each, according to a regulatory filing today. Opthotech originally sought to sell 5.72 million shares for $16 to $19 apiece, based on a filing from September 9.

Investor interest in biotechnology companies is surging, with the Nasdaq Biotechnology Index up more than 50 percent so far this year. Other drug-related companies including Quintiles Transnational Holdings Inc. and Portola Pharmaceuticals Inc. also offered more shares in their IPOs to capitalize on rising stock prices.

Opthotech, based in Princeton, New Jersey, has no revenue and operates at a loss. The company plans to use the IPO proceeds to fund trials of its most-advanced candidate, Fovista, to treat wet age-related macular degeneration, or wet AMD. That disease, if untreated, can cause severe vision loss, according to the filing.

Quintiles, a provider of testing services to drugmakers, is up 6.5 percent since its May 9 debut. Portola, developer of treatments for blood clots, has surged 68 percent through yesterday since its IPO on May 22.

Morgan Stanley and JPMorgan Chase & Co. are managing the IPO. Opthotech plans to list on the Nasdaq Stock Market under the symbol OPHT.

To contact the reporter on this story: Leslie Picker in New York at

To contact the editor responsible for this story: Jeffrey McCracken at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.